Navigation Links
Inhibitex Prices $47 Million Public Offering
Date:4/7/2011

ATLANTA, April 7, 2011 /PRNewswire/ -- Inhibitex, Inc. (Nasdaq: INHX) today announced that it has priced a public offering of 11,463,415 shares of its common stock, at a purchase price of $4.10 per share, for an aggregate offering amount of $47 million. The net proceeds to Inhibitex from the sale of the shares, after underwriting discounts and commissions and other offering expenses, are expected to be approximately $44 million.  Inhibitex has granted the underwriters a 30-day option to purchase up to approximately 1.7 million additional shares to cover over-allotments, if any. The offering is expected to close on April 12, 2011, subject to customary closing conditions.  The Company intends to use the net proceeds from the offering for working capital and general corporate purposes, including a Phase 2 clinical trial for INX-189, a nucleotide polymerase inhibitor that it is developing for the treatment of chronic hepatitis C infections, and research and development expenses related to its other development programs.  

Deutsche Bank Securities Inc. is acting as sole book-running manager. Canaccord Genuity Inc. is acting as Lead Manager, JMP Securities LLC is acting as Co-Manager, and Trout Capital LLC is acting as a financial advisor.

A shelf registration statement on Form S-3 relating to the shares was filed with the Securities and Exchange Commission ("SEC") and is effective.  A final prospectus supplement relating to the offering will be filed with the SEC. When available, copies of the final prospectus supplement and the prospectus relating to these securities may be obtained by contacting Deutsche Bank Securities, Inc. by sending a request to Deutsche Bank Securities Inc., Attn: Prospectus Department, 100 Plaza One, Jersey City, NJ 07311, Telephone number: 800-503-4611, Email: prospectusrequest@list.db.com.  Electronic copies of the prospectus supplement and accompanying prospectus will also be available on the website of the SEC at http://www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy shares of common stock of Inhibitex, Inc., nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About InhibitexInhibitex, Inc. is a clinical stage biopharmaceutical company focused on developing products to prevent and treat serious infectious diseases.  The Company's pipeline includes FV-100, which is in Phase 2 clinical development for the treatment of shingles, and INX-189, a nucleotide polymerase inhibitor in Phase 1 clinical development for the treatment of chronic hepatitis C infections.  The Company also has additional HCV nucleotide polymerase inhibitors in preclinical development and has licensed the use of its proprietary MSCRAMM® protein platform to Pfizer for the development of staphylococcal vaccines.  For additional information about the Company, please visit www.inhibitex.com.

Inhibitex® and MSCRAMM® are registered trademarks of Inhibitex, Inc.

Safe Harbor StatementThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements are often, but are not always, made through the use of words or phrases such as "anticipates," "intends," "estimate," "plans," "expects," "we believe," "we intend," and similar words or phrases, or future or conditional verbs such as "will," "would," "should," "potential," "could," "may," or similar expressions.  These statements  involve substantial risks and uncertainties, including risks relating to the completion of the registered public offering, including the satisfaction of customary closing conditions, the use of the anticipated proceeds from the offering, the Company's need to raise additional operating capital in the future, the Company's  history of losses, risks and costs of drug development, risk of regulatory approvals, reliance on collaborations and licenses, intellectual property risks, competition, market acceptance for the Company's products if any are approved for marketing, reliance on key personnel and other cautionary statements contained in the Company's public filings made with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the year ended December 31, 2010, as filed with the SEC on March 16, 2011. Given these uncertainties, you should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release.Contacts:Russell H. Plumb

Lee M. Stern, CFAChief Executive Officer

The Trout Group(678) 746-1136

(646) 378-2922rplumb@inhibitex.com

lstern@troutgroup.com
'/>"/>

SOURCE Inhibitex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock
2. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
3. Savient Pharmaceuticals Prices Underwritten Offering of Common Stock
4. Delcath Systems, Inc. Prices $30.6 Million Stock Offering
5. Warner Chilcott Prices Secondary Equity Offering
6. Neurocrine Biosciences, Inc. Prices Common Stock Offering
7. NCPA: AARP Report Finds Brand Name Drug Prices Soar as Large Pharmacy Benefit Managers Reap Windfall Profits
8. Volcano Corporation Prices $100 Million 2.875 Percent Convertible Senior Notes Due 2015
9. Canadian Health Care System Pressuring Manufacturers to Lower Drug-Eluting Stent Prices in US$55 Million Market
10. As Drug Prices Rise, Seniors are Advised to Review Their Medicare Prescription Coverage
11. Government Regulation of Drug Prices will Increase in Both Mature and Emerging Markets, Including Markets that Traditionally Play a Limited Role in Pharmaceutical Pricing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , Deutschland und GERMANTOWN, Maryland ... Zusammenarbeit mit Therawis bedient dringenden ... Brustkrebs   QIAGEN N.V. (NASDAQ: ... heute bekannt, eine Lizenz- und Entwicklungsvereinbarung mit Therawis ... für die Onkologie eingegangen zu sein. Ein erstes ...
(Date:5/25/2016)... 25, 2016 As illustrated by ... this month, the numbers and momentum of cannabis in ... into the billions, more research and development push the ... State of Legal Marijuana Markets Report  from from ArcView ... much of the increase in sector is attributed to ...
(Date:5/25/2016)... ReportsnReports.com adds "Chronic Cough ... provides an overview on therapeutic pipeline of Chronic ... therapeutics assessment by drug target, mechanism of action ... along with latest updates, and featured news and ... in the therapeutic development for Chronic Cough and ...
Breaking Medicine Technology:
(Date:5/28/2016)... ... 2016 , ... In a part of the city where’s it’s easy to spot the neon ... is hoping to attract diners with a taste for real food. , On ... doors to Cornerstone Grill, an urban casual restaurant focusing on dishes made by hand with ...
(Date:5/27/2016)... NJ (PRWEB) , ... May 27, 2016 , ... Two ... named as YWCA Tribute to Women and Industry (TWIN) 2016 honorees. The award ... their workplace. For this year, Geri Boone, Director of the MLTSS (Managed Long-Term Services ...
(Date:5/27/2016)... ... , ... With over 60 percent of acute stroke survivors being left unable ... aid in the rehabilitation process has steadily increased. Ekso Bionics had been working to ... to stroke. , Ekso Bionics has now received clearance from the U.S. Food and ...
(Date:5/27/2016)... York, NY (PRWEB) , ... May 27, 2016 ... ... partnered with Mediaplanet to help educate the many who are unaware of the ... dedicated to aphasia will run within the “Stroke Awareness” campaign. , The link ...
(Date:5/27/2016)... New York, NY (PRWEB) , ... May 27, 2016 , ... ... bolstered by inspiring human interest stories, which come courtesy of leaders in the nursing ... within the industry, from leading advocates and associations—namely Abilene Christian University. , As ...
Breaking Medicine News(10 mins):